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Abstract OBJECTIVE: The aim of this study was to assess the relationship between brain-
derived neurotrophic factor (BDNF) and sex hormones (estradiol [E2] and pro-
gesterone), using saliva samples obtained from healthy women.
METHODS: Forty female dental hygienist students were divided into groups 
according to being in the follicular phase or luteal phase. Saliva BDNF, E2, and 
progesterone levels were measured using a sandwich ELISA system. The correla-
tion between these factors was analyzed using Spearman’s index, and fluctuations 
of these levels in the whole menstrual cycle were investigated classifying the 
subjects by every 4 days according to the phase of their menstrual cycle.
RESULTS: Saliva BDNF variations strongly correlated with saliva E2 levels in 
the follicular phase (r=0.721, p=0.000) and luteal phase (r=0.770, p=0.000). The 
correlation coefficient showing the relationship between progesterone and BDNF 
levels in the luteal phase (r=0.371, p=0.157) was lower than that in the follicular 
phase (r=0.631, p=0.001). Moreover, the fluctuation of BDNF levels in the men-
strual cycle followed a similar pattern to that of E2.
CONCLUSIONS: We found that saliva BDNF and E2 levels were closely related 
in healthy young women. In particular, for first time, that correlation was inves-
tigated throughout the menstrual cycle. Monitoring of saliva BDNF may yield 
insight into women’s reproductive and mental health.
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INTRODUCTION
Brain-derived neurotrophic factor (BDNF) is a member 
of the neurotrophin family (NT), which includes nerve 
growth factor (NGF), NT-3, -4/5, -6, and -7. BDNF 
is abundantly expressed in the central and peripheral 
nervous system, and, in particular, in the hippocam-
pus (Saruta et al. 2010). Hippocampal BDNF plays an 
important functional role in learning and memory (Hall 
et al. 2000). Although it was originally identified in the 
nervous system, BDNF is now known to be expressed 
in a wide variety of non-neural cells, such as the lachry-
mal glands (Ghinelli et al. 2003), heart (Scarisbrick et al. 
1993), and retina (Seki et al. 2003) in rodents, as well as 
in the testis (Muller et al. 2006), lung (Ricci et al. 2004), 
and endothelial cells (Nakahashi et al. 2000) in humans. 
We previously reported that BDNF expression in the 
rat submandibular gland is up-regulated by chronic 
stress, and localization of BDNF mRNA and protein 
was observed in salivary acini cells in humans (Saruta 
et al. 2012). In recent years, immunohistochemical 
and in vitro studies have demonstrated BDNF expres-
sion in reproductive organs, including the ovaries 
(Kawamura et al. 2005), in particular in the granular 
cells (Domingue et al. 2011), and the endometrium 
(Krizsan-Agbas et al. 2003). Moreover, it was found 
that the ovaries specifically expressed a BDNF receptor, 
TrkB (Kawamura et al. 2009). These reports suggested 
that there is a close association between BDNF and the 
reproductive system in women.
Moreover, changes in plasma BDNF levels have been 
reported to occur in women throughout the menstrual 
cycle: studies have shown higher levels of BDNF during 
the luteal phase than in the follicular phase (Cubeddu 
et al. 2011). Hormone replacement therapy (HRT) is 
able to increase BDNF levels from menopausal levels 
to approximately those observed in the follicular phase 
(Begliuomini et al. 2007). Furthermore, estradiol (E2) 
is induced by BDNF in neural cells of the rat brain, 
including those in the hypothalamus and hippocampus 
(Scharfman & MacLusky 2008). E2 plays an important 
role in the modification of intra-tissue (Scharfman & 
MacLusky 2008) and plasma levels of BDNF (Begliuo-
mini et al. 2007). Interestingly, the BDNF profile of pre-
menstrual syndrome is characterized by a low plasma 
level in the luteal phase, despite increases in E2 levels 
(Cubeddu et al. 2011). Measurement of plasma BDNF 
levels during the menstrual cycle may have important 
implications in women’s health and reproduction.
The sensitivity and precision of the saliva E2 assay 
are comparable to those of assays of serum E2 for assess-
ing changes in hormone levels (Lu et al. 1999). The 
measurement of E2 and progesterone concentrations in 
saliva has become increasingly common over the past 
several years (Dame et al. 1989). The measurement of 
saliva E2 and progesterone levels during the post-awak-
ening period could provide information regarding the 
hypothalamus-pituitary-ovary axis response to awak-
ening (Ahn et al. 2011). In addition, using ELISA and 
western blotting, we have demonstrated that human 
saliva contains BDNF. Saliva BDNF concentrations in 
males tended to be lower than those in females (Saruta 
et al. 2012), resembling the profile of plasma BDNF 
(Lommatzch et al. 2005). To date, there are no studies 
evaluating the relationship between BDNF and sex hor-
mones in saliva. 
In recent years, analysis of saliva has become an 
attractive sampling approach. The collection of saliva is 
easier than venipuncture and can readily be repeated at 
frequent intervals (Ahn et al. 2011). These advantages 
allow for a better assessment of the diurnal rhythm-
mediated secretion of sex hormones and related factors, 
such as BDNF (Ahn et al. 2011). Thus, saliva testing 
may contribute to the monitoring of women’s health. 
Consequently, the aim of the present study was to 
assess correlations between BDNF and E2 as well as 
progesterone in the saliva of healthy female subjects.
MATERIALS AND METHODS
Subjects
The study was approved by the Ethics Committee of 
the Kanagawa Dental University, graduate school of 
Dentistry. Forty females, volunteer dental hygienist 
students, were included in the present study. They were 
divided into the following two groups: fertile women in 
the follicular phase (n=24), aged 21.0±3.5 y (mean±SD, 
range 19–32 y), with a body mass index (BMI) 19.4±1.5 
(range 16.2–21.9), and fertile women in the luteal phase 
(n=16), aged 23.0±3.9 (range 19–31 y), with a BMI 
19.6±1.6 (range 16.8–22.0). Each group was assessed 
both in the follicular phase (days 0–14) and in the luteal 
phase (days 15–28) of the menstrual cycle. Menstrual 
phase was determined based on self-reporting.
Prior to enrollment, participating subjects gave 
their written informed consent and they were asked to 
answer a questionnaire regarding age, weight, height, 
and menstrual cycles. Subjects with oral infective dis-
eases, current illness, under medication, or with aller-
gies, or a family history, or overweight (BMI ≥25.0) 
were excluded from this study. The mean menstrual 
cycles of all subjects lasted 27.9±4.8 days. 
Saliva collection
For 5 min prior to sample collection, subjects did not 
consume any food or drink, or brush their teeth. All 
samples were collected between 1 and 4 pm, within a 
10-min period, to minimize any possible effect of diur-
nal variation. All saliva samples were collected using 
the Salivette (Sarstedt Co. Ltd., Nümbrecht, Germany) 
absorbent method according to the manufacturer’s 
instructions. Briefly, participants were instructed place 
a cotton roll on the floor of the mouth for 5 min, or 
until the cotton was fully saturated with saliva, and then 
spit the cotton into the Salivette tube, which was sub-
sequently stored on ice. The tubes were centrifuged at 
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626 × g for 15 min at 4 °C and were then stored at –80 °C 
until required for use. Upon thawing, the samples 
were centrifuged once more to ensure complete debris 
removal, using the same conditions.
BDNF assay
Human BDNF was detected by sandwich ELISA 
according to the manufacturer’s instructions (CYT306; 
Millipore Corp, Bedford, MA, USA). All assays were 
performed in F-bottom 96-well plates (Nunc, Wies-
baden, Germany). Tertiary antibodies were conjugated 
to horseradish peroxidase and color was developed with 
tetramethylbenzidine and measured at 450/570 nm. 
The BDNF content was quantified against a standard 
curve; the detection limit of <4 pg/mL was calibrated 
with known amounts of human recombinant BDNF. All 
samples were tested twice, and the mean was calculated. 
Cross-reactivity to related NTs (NGF, NT-3, and NT-4) 
was less than 3%. Intra- and inter-assay coefficients of 
variation were 3.7% and 8.5%, respectively. Concentra-
tions were expressed as pg/mL (Goto et al. 2012).
E2 and progesterone assays
The saliva ELISA kit for measuring free 17β-estradiol 
and progesterone were used according to the manufac-
turer’s instructions (IBL, Hamburg, Germany) (Rijn et 
al. 2011). The lowest detectable levels of E2 and pro-
gesterone that could be distinguished from the zero 
standard were 0.4 pg/mL for E2 and 3.8 pg/mL for pro-
gesterone, at the 95% confidence limit. The intra- and 
inter-assay coefficients of variation were 2.6% and 2.1% 
for E2, and 4.7% and 5.3% for progesterone, respectively.
Parameters and statistical analysis
ELISA data are reported as a mean ± SD. Statistical 
analysis was carried out using SPSS software (version 
17.0; SPSS Inc., Chicago, IL, USA). We used the Mann–
Whitney test to evaluate differences between follicular 
and luteal phase subjects for each parameter. A correla-
tion index (Spearman’s index) was computed in order to 
investigate the relationship among saliva BDNF levels 
and E2 as well as progesterone levels. The p-values of 
0.05 or less were accepted as significant.
RESULTS
Differences among parameters between 
follicular phase and luteal phase subjects
Data from subjects in the follicular phase or luteal 
phase, as determined by ELISA, are compared in 
Table 1. Although these levels tended to be higher in 
individuals in the luteal phase than those of subjects in 
the follicular phase, the differences were not significant.
Correlation index
There were positive correlations between saliva E2 and 
progesterone levels for subjects in the follicular phase 
and for individuals in the luteal phase, represented in 
Figure 1. Saliva BDNF variations strongly correlated 
with saliva E2 changes in the follicular phase and in 
the luteal phase (Figure 2). Although saliva BDNF and 
progesterone levels correlated in individuals in the fol-
licular phase, no correlations were noted in individuals 
in the luteal phase, as shown in Figure 3. 
Variation of saliva BDNF, E2, and 
progesterone during menstrual cycle
By classifying subjects by every 4 days according to the 
phase of their menstrual cycle, we investigated the vari-
ations in saliva BDNF and sex hormone levels during 
the whole of the menstrual cycle (Figure 4). BDNF 
levels were found to show two peaks: one lower peak 
Tab. 1. Differences between follicular phase and luteal phase.
Follicular phase Luteal phase
Mean SD Mean SD
BDNF 8.510 8.657 13.106 14.255
E2 7.264 4.485 8.254 5.297
Progesterone 60.407 46.090 87.258 49.550
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Fig. 1. Scatterplot showing the relationship between saliva E2 levels 
and saliva progesterone levels of subjects in the follicular phase 
and those in the luteal phase.
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at the 13th–16th day (14.916±7.702) and one tall peak 
at the 21st–24th day (22.309±29.990) during a normal 
menstrual cycle. Similar to BDNF, E2 levels also showed 
two peaks (13th–16th day: 8.858±4.863; 21st–24th day: 
10.007±8.154). Moreover, the 
levels of progesterone peaked at 
the 13th–20th day (13th–16th day: 
98.591±52.624, 17th–20th day: 
98.835±67.356).
DISCUSSION
Saliva E2 and progesterone con-
centrations tended to be higher in 
subjects in the luteal phase than in 
those in the follicular phase, but 
these differences, as determined 
using an ELISA system, were not 
statistically significant. In addi-
tion, there were significant correla-
tions between E2 and progesterone 
levels in the saliva of both groups 
of subjects. Lu et al. reported that 
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Fig. 2. Scatterplot showing the relationship between saliva BDNF 
levels and saliva E2 levels in subjects in the follicular phase and 
those in the luteal phase.
Fig. 3. Scatterplot showing the relationship between saliva BDNF 
levels and saliva progesterone levels of subjects in the follicular 
phase and those in the luteal phase.
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Fig. 4. Changes in saliva BDNF, E2, and progesterone levels during the menstrual cycle in 
young healthy women. Average levels for every 4 days of the cycle are presented.
the sensitivity and precision of saliva E2 and proges-
terone assays were comparable with assays of blood 
E2 and progesterone for assessing changes in hormone 
levels (Lu et al. 1999). It is well-known that blood and 
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saliva concentrations of E2 and progesterone are related 
(Celec et al. 2009; Dame et al. 1989). Since sex hormone 
levels, including those of E2 and progesterone, are high-
est in blood during the luteal phase (Cubeddu et al. 
2011; Okifji & Turk 2006), our results can be attributed 
to the increase of E2 and progesterone concentrations 
in blood. If the number of subjects had been sufficient, 
the difference between levels of individuals in the fol-
licular and luteal phase may have been significant.
We found that there was a strong linear correlation 
between BDNF and E2 levels in saliva. Experimen-
tal studies on animal models showed that estrogen 
treatment of ovariectomized rats improved learn-
ing acquisition and memory performance (O’Neal 
et al. 1996). Indeed, E2 increased the dendritic spine 
number though a BDNF-dependent mechanism (Segal 
& Murphy 2001). In humans, it has been reported that 
there is a positive relationship between plasma BDNF 
and E2 levels during the menstrual cycle, based on a 
study of five healthy women, with a correlation index 
ranging from 0.6144 to 0.8542 (Begliuomini et al. 
2007). Interestingly, BDNF levels were increased by 
HRT (including E2) in subjects showing a low plasma 
BDNF level, such as amenorrhoeic women and post-
menopausal women (Begliuomini et al. 2007). HRT 
also improved cognitive functions in postmenopausal 
women (Genazzani et al. 2005; Prelevic et al. 2005). 
These previous studies and our results established that 
estrogens and BDNF were reciprocally and positively 
involved in various situations. 
Moreover, when we investigated the fluctuations 
in the levels of BDNF and sex hormones during the 
menstrual cycle, the fluctuation pattern of BDNF was 
similar to that of E2. Sex hormone levels in blood differ 
in terms of their peaks during the menstrual cycle: E2 is 
elevated in the pre-ovulatory and middle luteal phase, 
whereas progesterone is increased during the middle 
luteal phase (Begliuomini et al. 2007). Interestingly, in 
the present study, reflecting the changes in blood levels, 
saliva E2 levels showed two peaks (13th–16th and 21st–
24th day), although saliva progesterone levels differed 
from the blood levels, because it was not examined con-
secutively throughout the whole menstrual cycle in all 
subjects. Thus, our findings indicated the probability 
that changes in saliva BDNF levels are associated with 
those of E2 during the menstrual cycle. This suggests 
that measurement of saliva BDNF may be useful in 
monitoring reproductive health in women.
On the other hand, the source of saliva BDNF has 
never been investigated in detail, although saliva clearly 
contains BDNF protein, as determined by western 
blotting and ELISA analysis. Saruta et al. reported that 
BDNF mRNA and protein are expressed in the acini 
cells of the human salivary gland (Saruta et al. 2012). In 
addition, human salivary gland tissue expresses estro-
gen receptor (ER) mRNA, as determined by RT-PCR 
(Leimola-Virtanen et al. 2000), but does not express E2. 
Additionally, HRT can improve both the quantity and 
the quality of salivary gland function (Laine & Leimola-
Virtanen 1996). It is thought that E2 plays crucial roles 
in the salivary gland. It is possible that saliva BDNF may 
be induced and/or released from acini cells, mediated by 
E2–ER interaction, and is not only derived from blood. 
In addition, the saliva BDNF levels of subjects in 
the follicular phase tended to be lower than those in 
the luteal phase; thus, it was reasonable that a decrease 
in saliva BDNF was induced by a decrease in blood 
E2 levels. Thus, measurement of saliva BDNF may be 
useful to determine the effects of HRT as a marker of 
increased blood BDNF.
The relationship between progesterone and BDNF 
levels in subjects in the follicular phase was significant, 
but this correlation was non-significant in the luteal 
phase. In recent years, it has been shown that proges-
terone attenuated the E2-mediated increase in the levels 
of BDNF and the BDNF receptor, TrkB, in cultured hip-
pocampal slices (Aguirre & Baudry 2009). Progesterone 
probably suppresses BDNF expression (Bimonte-Nel-
son et al. 2004). However, the interplay between BDNF 
and progesterone remains controversial (Cubeddu et 
al. 2011). Our results also suggest that BDNF levels are 
strongly correlated with E2 levels, rather than with pro-
gesterone levels in saliva, which supports the previous 
report by Begliuomini et al. (2007). 
Several studies have shown that there are associa-
tions between a decrease in blood BDNF and neurolog-
ical diseases, such as depression, Alzheimer’s disease, 
and Parkinson’s disease (Connor et al. 1997; Parain et al. 
1999; Tsukinoki & Saruta 2012). In addition, individu-
als with premenstrual syndrome and mood disorder 
in the postnatal phase have been reported to demon-
strate lower blood BDNF levels than healthy women 
(Cubeddu et al. 2011; Lommatzsch et al. 2006). More-
over, it has been shown that a long-term deficiency of 
BDNF, such as that observed during menopause, may 
pose a higher risk for the development of mental dis-
orders (Begliuomini et al. 2007). BDNF seems to be 
strongly involved in neurological diseases related to the 
reproductive cycle of women. It would be interesting to 
determine the saliva BDNF level profiles in various dis-
eases known to be associated with a low blood BDNF 
levels.
CONCLUSION
We found that saliva BDNF and E2 levels were closely 
related in healthy young women. In particular, for first 
time, this relationship was investigated throughout the 
menstrual cycle, including the follicular phase and the 
luteal phase. Since blood BDNF levels may be modi-
fied during the menstrual cycle, depending on E2 levels, 
measurement of the saliva BDNF–E2 balance may be 
useful for monitoring reproductive function. Examin-
ing saliva BDNF levels may also provide useful infor-
mation for assessing women’s mental health, although 
further studies are needed to support this proposal. 
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